Venxxiva (tiopronin delayed-release)
Indications for Prior Authorization
Venxxiva (tiopronin delayed-release)
-
For diagnosis of Cystinuria
Indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.
Criteria
Venxxiva
For state-mandated plans in Illinois or other states where applicable: Step therapy requirements do NOT apply. Beginning January 1, 2026, step therapy requirements or use of the authorization of alternative covered medications in a manner that effectively creates a step therapy requirement will not be imposed.
Step Therapy
Length of Approval: 12 Month(s)
- Requested drug is being used for a Food and Drug Administration (FDA) - approved indication AND
- Trial and intolerance (of a minimum 30-day supply) to both of the following:
- Brand Thiola EC
- generic tiopronin DR
P & T Revisions
1970-01-01, 2025-12-18, 2025-02-05
References
- Venxxiva Prescribing Information. Cycle Pharmaceuticals Ltd. Cambridge, UK. December 2024.
Revision History
- 1970-01-01: No criteria changes
- 2025-12-18: no criteria changes, added IL statute operational note
- 2025-02-05: New Program
HEALTHY LIVING